US4556556A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccine for the prevention of vesicular stomatitis virus infection
Assignee: Diamond Scientific Co
•
Filing: 1984-03-23
•
Granted: 1985-12-03
•
Expires: 2004-03-23
Abstract
Abstract Novel vaccines for vesicular stomatitis virus are prepared by psoralen inactivation of the live virus under mild conditions in an inert atmosphere. The resulting inactivated virus can be used as a vaccine for inoculation of susceptible hosts to inhibit VSV infection.
Inventors
- 👤 Gary P. Wiesehahn
- 👤 Richard E. Giles
- 👤 David R. Stevens
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 02:42
CPC Classifications
C; C12; C12N; C12N7/00; A; A61; A61K; A61K39/00; A61K39/12; A61K39/205; A61K2039/51; A61K2039/525; A61K2039/5252; A61K2039/555; A61K2039/55505; A61K2039/55511; A61K2039/55566; C12N2760/00; C12N2760/00011; C12N2760/20011; C12N2760/20211; C12N2760/20234; C12N2760/20261; C12N2760/20263; Y; Y10; Y10S; Y10S424/00; Y10S424/813
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
94 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis virus (VSV), which vaccine comprises an immunologic adjuvant and about a 10 6 to 10 9 pfu/dose effective dosage amount of at least one inactivated VSV serotype, wherein the VSV has been inactivated by exposure to long wavelength ultraviolet light at a temperature below about 40° C. under conditions excluding free oxygen and in an inert atmosphere in the presence of an inactivating furocoumarin for a time sufficient to render said VSV non-infectious, whereby the immunogenicity is substantially retained.
Claim 2
Dependent Claim
94 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis virus (VSV), which vaccine comprises an immunologic adjuvant and about a 10 6 to 10 9 pfu/dose effective dosage amount of at least one inactivated VSV serotype, wherein the VSV has been inactivated by exposure to long wavelength ultraviolet light at a temperature below about 40° C. under conditions excluding free oxygen and in an inert atmosphere in the presence of an inactivating furocoumarin for a time sufficient to render said VSV non-infectious, whereby the immunogenicity is substantially retained.
Claim 3
Dependent Claim
11 words
A vaccine according to claim 1, wherein said furocoumarin is 4'-aminomethyl-4,5',8-trimethylpsoralen.
Claim 4
Dependent Claim
15 words
A vaccine according to claim 2, wherein said VSV is of the New Jersey serotype.
Claim 5
Dependent Claim
15 words
A vaccine according to claim 1, wherein said vaccine includes aluminum hydroxide as an adjuvant.
Claim 6
Dependent Claim
13 words
A vaccine according to claim 1, wherein said vaccine includes oil emulsion adjuvant.
Claim 7
Dependent Claim
19 words
A vaccine according to claim 1, wherein said VSV is inactivated in the presence of a singlet oxygen scavenger.
Claim 8
Dependent Claim
22 words
A vaccine according to claim 1, wherein said VSV is grown in substantially confluent monolayers of host cells immediately prior to inactivation.
Claim 9
Dependent Claim
94 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis (VSV), which comprises VSV New Jersey serotype inactivated by irradiation with long wavelength ultraviolet light in the presence of 4'-amino-methyl-4,5'-8-trimethylpsorlen at a temperature in the range of about -10° to 15° C. for a time sufficient to render said VSV non-infectious under conditions substantially excluding free oxygen and in an inert atmosphere in which the VSV substantially retains its immunogenicity, said VSV being present at about 10 6 to 10 8 pfu/dose in a physiologically acceptable immunologic adjuvant carrier.
Claim 10
Dependent Claim
94 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis (VSV), which comprises VSV New Jersey serotype inactivated by irradiation with long wavelength ultraviolet light in the presence of 4'-amino-methyl-4,5'-8-trimethylpsorlen at a temperature in the range of about -10° to 15° C. for a time sufficient to render said VSV non-infectious under conditions substantially excluding free oxygen and in an inert atmosphere in which the VSV substantially retains its immunogenicity, said VSV being present at about 10 6 to 10 8 pfu/dose in a physiologically acceptable immunologic adjuvant carrier.
Claim 11
Dependent Claim
15 words
A vaccine according to claim 8, wherein said vaccine includes aluminum hydroxide as an adjuvant.
Claim 12
Dependent Claim
13 words
A vaccine according to claim 8, wherein said vaccine includes oil emulsion adjuvant.
Claim 13
Dependent Claim
19 words
A vaccine according to claim 8, wherein said VSV is inactivated in the presence of a singlet oxygen scavenger.
Claim 14
Dependent Claim
84 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis virus (VSV), which vaccine comprises an immunologic adjuvant and about a 10 6 to 10 9 pfu/dose effective dosage amount of at least one inactivated VSV serotype, wherein the VSV has been inactivated by exposure to long wavelength ultraviolet light in the substantial absence of oxygen at a temperature below about 40° C. in the presence of an inactivating furocoumarin for a time sufficient to render said VSV non-infectious.
Claim 15
Dependent Claim
84 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis virus (VSV), which vaccine comprises an immunologic adjuvant and about a 10 6 to 10 9 pfu/dose effective dosage amount of at least one inactivated VSV serotype, wherein the VSV has been inactivated by exposure to long wavelength ultraviolet light in the substantial absence of oxygen at a temperature below about 40° C. in the presence of an inactivating furocoumarin for a time sufficient to render said VSV non-infectious.
Claim 16
Dependent Claim
82 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis (VSV), which comprises VSV New Jersey serotype inactivated by irradiation in the substantial absence of oxygen with low wavelength ultraviolet light in the presence of 4'-aminomethyl-4,5',8-trimethylpsoralen at a temperature in the range of about -10° C. to 15° C. for a time sufficient to render said VSV non-infectious, said VSV being present at about 10 6 to 10 8 pfu/dose in a physiologically acceptable immunologic adjuvant carrier.
Claim 17
Dependent Claim
82 words
A vaccine useful for inoculation of a mammalian host susceptible to infection by vesicular stomatitis (VSV), which comprises VSV New Jersey serotype inactivated by irradiation in the substantial absence of oxygen with low wavelength ultraviolet light in the presence of 4'-aminomethyl-4,5',8-trimethylpsoralen at a temperature in the range of about -10° C. to 15° C. for a time sufficient to render said VSV non-infectious, said VSV being present at about 10 6 to 10 8 pfu/dose in a physiologically acceptable immunologic adjuvant carrier.
References Cited (Backward Citations)
US3083142A
Cited
US3149036A
Cited
US3075883A
Cited
US3492399A
Cited
US3594471A
Cited
US3790665A
Cited
US3629413A
Cited
US3869546A
Cited
US4069313A
Cited
US4124598A
Cited
US4196281A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-12-02 | 1989-06-03 | 1989-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-12-02 | 1993-06-03 | 1993-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-12-02 | 1997-06-03 | 1997-12-03 | $7700.00 | Window Closed / Lapsed |